C225

(redirected from IMC-C225)

C225

A chimeric IgG antibody with a strong binding affinity for epidermal growth factor (EGF) receptor, which blocks ligand—EGF, TGF α, etc.—binding and inhibits cell proliferation. C225 made it through to Phase III trials, during which time it was renamed cetuximab (Erbitux), and has proved to be a blockbuster cancer drug for head and neck cancer, colorectal and other cancers.
References in periodicals archive ?
Enhanced anti-tumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Future issues of Medical Update will feature excerpts of Post interviews with leading researchers and specialists, along with an investigation of the late-breaking results of ImClone's IMC-C225 and its ability to arrest growth in advanced pancreatic cancers.
IMC-C225 is an investigational monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of cancer cells.
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.